To the full analysis
Buyback calculator for Genscript Biotech
Genscript Biotech stock: key metrics
1548.HKGenscript Biotech had an operating margin of 26.6% and a return on invested capital (ROIC) of 5.2% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2013 | 63.4% | 14.3% | 10.0% |
| 2014 | 63.0% | 10.2% | 8.8% |
| 2015 | 65.8% | 12.6% | 20.2% |
| 2016 | 66.4% | 21.7% | 22.8% |
| 2017 | 68.5% | 25.9% | 17.1% |
| 2018 | 68.6% | 2.2% | 9.2% |
| 2019 | 66.0% | −48.0% | −35.5% |
| 2020 | 65.5% | −52.3% | −52.4% |
| 2021 | 57.6% | −77.4% | −73.2% |
| 2022 | 48.6% | −70.0% | −36.3% |
| 2023 | 48.3% | 4.7% | no data |
| 2024 | 45.8% | 1.6% | no data |
| 2025 | 57.7% | 26.6% | −55.5% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2013 | 11.4% | 20.5% | 7.2% |
| 2014 | 10.0% | 14.9% | 6.7% |
| 2015 | 11.7% | 19.0% | 9.6% |
| 2016 | 14.7% | 43.7% | 11.6% |
| 2017 | 12.0% | 37.3% | 5.2% |
| 2018 | 4.4% | 0.9% | 2.3% |
| 2019 | −25.3% | −14.3% | −10.9% |
| 2020 | −22.7% | −17.5% | −14.2% |
| 2021 | −34.3% | −20.1% | −16.1% |
| 2022 | −22.4% | −18.0% | −8.9% |
| 2023 | no data | 6.5% | no data |
| 2024 | no data | 0.3% | no data |
| 2025 | −13.5% | 5.2% | −11.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 16 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.